Chinese Fibromyalgia Market is expected to grow at a CAGR of 18.7% during the forecast period 2017-2022

1
Chinese Fibromyalgia Market is expected to grow
at a CAGR of 18.7 during the forecast period
2017-2022
SAMPLE
FOR MORE INFO
2
Chinese Fibromyalgia Market
Market Highlights Fibromyalgia syndrome
co-exists with other painful conditions, such as
migraine and other types of headaches,
temporomandibular joint disorders, irritable
bowel syndrome (IBS), and interstitial cystitis.
The treatment of fibromyalgia includes both
targeted and symptomatic approach. Till date,
there are only three FDA approved drugs for the
fibromyalgia treatment, i.e., Lyrica (PFIZER),
Cymbalta (Eli Lilly and Company), and Savella
(Allergan plc). However, there are few other
drugs prescribed by physicians to control the
symptoms of fibromyalgia such as pain relievers,
muscle relaxants, and traditional Chinese
medicine. Growing geriatric population,
increasing cases of rheumatic diseases, growing
awareness among the population, and rising
incidences of traumatic stress and road accidents
are the key factors driving the Chinese
fibromyalgia market. According to a study
published in the Arthritis Care Research
journal in 2017, fibromyalgia and related
symptoms worsen the functional status of
individuals with rheumatoid arthritis. Around
15-30 of patients with rheumatic disorders have
co-morbid fibromyalgia syndrome. Request For
Sample Report https//www.marketresearchfuture.co
m/sample_request/5630
3
Chinese Fibromyalgia Market
Regional Analysis South Central China accounted
for the major share of the market owing to the
rising prevalence of fibromyalgia in this region.
Rising cases of chronic rheumatic diseases are
also capable of fuelling the fibromyalgia market
in China. Prevalence of rheumatoid arthritis is
around 0.35, with the significantly higher rate
in Northern China as compared to the Southern
part. The rising healthcare expenditure is also
propelling the growth of the market. In China,
the total expenditure on health per capita in
2014 was USD 731, as per the World Health
Organization (WHO) in 2015. The health
expenditure in China grew at a rate of 11.6 per
year, suggested by a study published in BMC
Health Services Research journal in 2017. This
rate is much faster than the growth of the
countrys economy, i.e., 9.9 per year. Get
Discount _at_ https//www.marketresearchfuture.com/ch
eck-discount/5630
4
Chinese Fibromyalgia Market
Segmentation The Chinese fibromyalgia market is
segmented on the basis of diagnosis, treatment,
and end-user. On the basis of the diagnosis, the
market is classified into laboratory evaluation
and presence of central sensitization. On the
basis of the treatment, the market is segmented
into targeted treatment and symptomatic
treatment. On the basis of the end-users, the
market is segmented into hospitals, clinics,
diagnostic centers, and others.
5
ABOUT US
MARKET RESEARCH FUTURE At Market Research Future
(MRFR), we enable our customers to unravel the
complexity of various industries through our
Cooked Research Report (CRR), Half-Cooked
Research Reports (HCRR), Raw Research Reports
(3R), Continuous-Feed Research (CFR), and Market
Research Consulting Services. MRFR team have
supreme objective to provide the optimum quality
market research and intelligence services to our
clients. Our market research studies by products,
services, technologies, applications, end users,
and market players for global, regional, and
country level market segments, enable our clients
to see more, know more, and do more, which help
to answer all their most important questions. In
order to stay updated with technology and work
process of the industry, MRFR often plans
conducts meet with the industry experts and
industrial visits for its research analyst
members. For more information kindly visit
www.marketresearchfuture.com or contact us at
info_at_marketresearchfuture.com Copyright 2018
Market Research Future All Rights Reserved. This
document contains highly confidential information
and is the sole property of Market Research
Future. No part of it may be circulated, copied,
quoted, or otherwise reproduced without the
written approval of Market Research Future.
6
(No Transcript)